Eli Lilly And Co (N:LLY)

Nov 13, 2019 04:07 pm ET
Boehringer Ingelheim and Lilly announce outcome of FDA Advisory Committee meeting for empagliflozin 2.5 mg as adjunct to insulin for adults with type 1 diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 13, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 14 to 2 that the benefits of empagliflozin 2.5 mg do not outweigh the risks to support approval as an adjunct to insulin for adults with type 1 diabetes. Empagliflozin 2.5 mg is an SGLT2 inhibitor being developed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY). A separate brand name has been proposed for empagliflozin 2.5 mg in type 1 diabetes. ...
Nov 12, 2019 07:30 am ET
Boehringer Ingelheim and Lilly initiate first ever study to assess Jardiance® in people hospitalized for acute heart failure who have been stabilized
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced the initiation of EMPULSE, the sixth phase III study in the Jardiance® (empagliflozin) heart failure program. The study will assess whether in-hospital administration of Jardiance 10 mg daily improves heart failure outcomes when initiated in people hospitalized for any type of acute heart failure event once they have been stabilized. The study will include participants both with and without type 2 diabetes....
Nov 12, 2019 06:00 am ET
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz® (ixekizumab) Versus Humira® (adalimumab) Trial in Psoriatic Arthritis
INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the 52-week results from the Phase 3b/4 SPIRIT-Head-to-Head (H2H) study of Taltz® (ixekizumab) versus Humira® (adalimumab) in biologic-naïve patients with active psoriatic arthritis (PsA). The results are being presented as a late-breaking oral presentation at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) Annual Meeting in Atlanta....
Nov 12, 2019 05:45 am ET
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
INDIANAPOLIS, Nov. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented detailed results today demonstrating Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a 52-week placebo-controlled Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients with objective signs of inflammation who are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve. The data are being presented at the American College of Rheumatology (ACR)/Association of Rheumatology Professi...
Nov 08, 2019 05:45 am ET
Lilly Reinforces its Commitment to Rheumatology through Data Showcased at the ACR/ARP Annual Meeting
INDIANAPOLIS, Nov. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology (ACR)/Association of Rheumatology Professionals (ARP) annual meeting taking place Nov. 8-13, 2019 in Atlanta. The presentations will highlight the latest therapeutic data available in chronic rheumatologic conditions including radiographic axial spondyloarthritis, also known as ankylosing spondylitis (AS); psoriatic arthritis (PsA) and rheumatoid arthritis (RA), along with the la...
Nov 07, 2019 11:50 am ET
Lilly Announces the Pricing Terms of its Cash Tender Offer for Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities
INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the pricing terms of its previously announced cash tender offer for up to $2,000,006,000 aggregate principal amount of its outstanding debt securities....
Nov 07, 2019 08:00 am ET
Lilly Announces the Early Tender Results and Upsizing of Its Pending Cash Tender Offer to Up to $2,000,006,000 Aggregate Principal Amount of Its Outstanding Debt Securities
INDIANAPOLIS, Nov. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the early tender results for its previously announced cash tender offer of its outstanding debt securities.  Lilly also announced that it had increased the previously announced tender cap from $2,000,000,000 to $2,000,006,000 aggregate principal amount of its debt securities, subject to further increase in its sole discretion.  Except as described in this press release, all other terms of the tender offer as described in the Offer to Purchase, dated October 24, 2019, and the related Letter of Transmi...
Nov 06, 2019 08:00 am ET
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019
INDIANAPOLIS, Nov. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that multiple abstracts from its LOXO-305 program have been accepted for presentation at the 61st American Society of Hematology Annual Meeting and Exposition to be held December 7-10, 2019 in Orlando, Florida. LOXO-305 is a next-generation, highly selective, non-covalent BTK inhibitor....
Nov 04, 2019 03:15 pm ET
Lilly to Participate in Credit Suisse 28th Annual Healthcare Conference
INDIANAPOLIS, Nov. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Credit Suisse 28th Annual Healthcare Conference on Wednesday, November 13, 2019. Anne White, president of Lilly Oncology, Kimberly Blackwell, M.D., vice president, early phase clinical research, and Maura Dickler, M.D., vice president, oncology late phase development, will participate in a fireside chat at 10:35 a.m., Eastern Time. ...
Nov 04, 2019 08:00 am ET
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®
- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease...
Nov 04, 2019 08:00 am ET
Boehringer Ingelheim and Lilly modernise alliance to focus full expertise on Jardiance®
- Alliance to focus combined expertise and investment to maximise Jardiance® for people with type 2 diabetes, heart failure, and chronic kidney disease...
Oct 24, 2019 10:17 am ET
Lilly Announces Cash Tender Offer for Up to $2.0 Billion Aggregate Principal Amount of Its Outstanding Debt Securities
INDIANAPOLIS, Oct. 24, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has commenced a cash tender offer for up to $2.0 billion aggregate principal amount (the "tender cap") of specified series of its outstanding debt. Pursuant to the tender offer, Lilly is offering to purchase, under certain conditions and subject to certain limitations, its 3.950% Notes due 2047, 3.700% Notes due 2045, 3.875% Notes due 2039, 7.125% Notes due 2025, 6.77% Notes due 2036, 5.950% Notes due 2037, 5.55% Notes due 2037, 5.50% Notes due 2027, 4.650% Notes due 2044, 3.100% Notes due 2...
Oct 23, 2019 06:25 am ET
Lilly Reports Strong Third-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2019....
Oct 23, 2019 06:00 am ET
Enrique Conterno, Senior Vice President and President of Lilly Diabetes and Lilly USA, to Retire at End of Year; Mike Mason to Succeed Conterno
INDIANAPOLIS, Oct. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will retire at the end of the year after 27 years of service with the company. Mike Mason, who currently serves as senior vice president, connected care & insulins, will succeed Conterno. ...
Oct 21, 2019 02:45 pm ET
Lilly Declares Fourth-Quarter 2019 Dividend
INDIANAPOLIS, Oct. 21, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2019 of $0.645 per share on outstanding common stock. ...
Oct 16, 2019 06:45 am ET
Lilly Announces Phase 3 Study in Patients with Metastatic Pancreatic Cancer Did Not Meet Primary Endpoint of Overall Survival
INDIANAPOLIS, Oct. 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced top-line results from its Phase 3 SEQUOIA trial evaluating pegilodecakin plus FOLFOX (folinic acid, 5-FU, oxaliplatin) compared to FOLFOX alone in patients with metastatic pancreatic cancer whose disease had progressed during or following a first-line gemcitabine-containing regimen. The SEQUOIA trial did not meet its primary endpoint of overall survival....
Oct 12, 2019 06:45 am ET
Lilly Presents Positive Results for Taltz® (ixekizumab) in Pediatric Patients with Moderate to Severe Plaque Psoriasis at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congres
INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant 75 percent improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score (PASI 75) and 81 percent of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1). Results of the st...
Oct 11, 2019 03:48 pm ET
Lilly's REYVOW™ (lasmiditan), The First and Only Medicine in a New Class of Acute Treatment for Migraine, Receives FDA Approval
INDIANAPOLIS, Oct. 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved REYVOW™ (lasmiditan) an oral medication for the acute treatment of migraine, with or without aura, in adults. REYVOW has a unique mechanism of action and is the first and only FDA-approved medicine in a new class of acute treatment for migraine (serotonin (5-HT)1F receptor agonists)....
Oct 09, 2019 12:31 pm ET
Verzenio™ (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
Eli Lilly and Company (NYSE: LLY) announced that Verzenio™ (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor...
Oct 08, 2019 06:45 am ET
Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress
INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European Academy of Dermatology and Venereology (EADV) Congress taking place Oct. 9-13 in Madrid, Spain. The research being highlighted at this year's meeting reinforces Lilly's commitment to developing treatments for individuals living with dermatological conditions such as psoriasis, psoriatic arthritis, atopic dermatitis and alopecia areata. ...
Oct 07, 2019 06:45 am ET
Lilly's CYRAMZA® (ramucirumab) Phase 3 Data in First-Line EGFR-Mutated Non-Small Cell Lung Cancer Published in The Lancet Oncology
INDIANAPOLIS, Oct. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results from the global Phase 3 RELAY trial of CYRAMZA® (ramucirumab) in previously untreated patients with metastatic EGFR-mutated non-small cell lung cancer (NSCLC) were published in The Lancet Oncology. ...
Oct 03, 2019 09:25 am ET
Lilly Announces Voluntary Delisting from Euronext Paris
INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that it has requested the delisting of its shares (ISIN US5324571083) ("Lilly Shares") from Euronext Paris due to the very low trading volume, costs and administrative requirements related to its secondary listing on Euronext Paris. The Board of Directors of Euronext Paris S.A. has approved this request.  ...
Oct 03, 2019 06:45 am ET
New Head-to-Head Data Show Taltz® (ixekizumab) Superiority versus TREMFYA® (guselkumab) in People with Moderate to Severe Plaque Psoriasis
INDIANAPOLIS, Oct. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented detailed data at the 5th Annual Maui Derm NP+PA Fall meeting from the Phase 4 IXORA-R study, the first head-to-head (H2H) study between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint. Taltz met the primary endpoint of superiority vs. TREMFYA in the proportion of patients with moderate to severe plaque psoriasis achieving complete skin clearance as measured by PASI 100 at Week 12, as well as key secondary endpoints. The s...
Oct 02, 2019 04:30 pm ET
Lilly Confirms Date and Conference Call for Third-Quarter 2019 Financial Results Announcement
INDIANAPOLIS, Oct. 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its third-quarter 2019 financial results on Wednesday, October 23, 2019. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance....
Sep 29, 2019 10:30 am ET
Lilly Announces Positive Registrational Data for Selpercatinib (LOXO-292) in Heavily Pretreated RET-Altered Thyroid Cancers
INDIANAPOLIS, Sept. 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib1 monotherapy, also known as LOXO-292, for the treatment of RET-altered thyroid cancers. RET-altered thyroid cancers are comprised of two different populations, RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancers. In the RET-mutant MTC registration dataset consisting of the first 55 enrolled patients with prior cabozantinib and/or vandetanib2, selpercatinib treatment res...
Sep 29, 2019 10:30 am ET
Verzenio® (abemaciclib) Significantly Extends Life by a Median of 9.4 Months for Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2 Study
INDIANAPOLIS, Sept. 29, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with fulvestrant significantly extended life by a median of 9.4 months in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer previously treated with endocrine therapy (median of 46.7 months vs. median of 37.3 months with placebo plus fulvestrant; HR: 0.757; 95% CI: 0.606, 0.945; P = 0.0137). Results from the Phase 3 MONARCH 2 clinical trial, which included both pre/peri- an...
Sep 23, 2019 06:45 am ET
Lilly Oncology to Present Robust Data across Its Growing Portfolio at ESMO 2019
INDIANAPOLIS, Sept. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced data from a number of studies across the company's oncology product portfolio will be presented at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, September 27 - October 1, 2019. Data from 14 oral presentations and posters – including five late-breaking abstracts – underscore Lilly Oncology's dedication to developing and delivering innovative new medicines that will make a meaningful difference to people living with cancer....
Sep 20, 2019 06:45 am ET
CHMP Issues Positive Opinion to Expand Trulicity® (dulaglutide) Label to Include Results from REWIND Cardiovascular Outcomes Trial
INDIANAPOLIS, Sept. 20, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending an update to the Trulicity® (dulaglutide) label and indication statement. The committee agreed the label should include results from the REWIND cardiovascular (CV) outcomes trial, which achieved a significant 12 percent risk reduction in major adverse cardiovascular events (MACE). ...
Sep 19, 2019 04:30 pm ET
Lilly Announces Webcast to Discuss ESMO 2019 Presentations
INDIANAPOLIS, Sept. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Wednesday, October 2, 2019 to discuss the company's presentations at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain. Remarks will focus primarily on data being presented for selpercatinib (LOXO-292) and Verzenio (abemaciclib). The webcast will begin at 9:00 a.m. Eastern Daylight Time....
Sep 09, 2019 03:20 am ET
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung
INDIANAPOLIS, Sept. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today presented data from the LIBRETTO-001 clinical trial intended to support the registration of oral selpercatinib[1] monotherapy, also known as LOXO-292, for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC). In the registration dataset consisting of the first 105 enrolled RET fusion-positive NSCLC patients with prior platinum-based chemotherapy, selpercatinib treatment resulted in a 68 percent objective response rate (ORR) (95% CI: 58-76%). This population was heavily pretreated (median of...
Sep 05, 2019 03:00 pm ET
Lilly's Pain Clinical Trial Protocol Selected for FDA Complex Innovative Trial Designs Pilot Meeting Program
INDIANAPOLIS, Sept. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has accepted its application to enter the Complex Innovative Trial Designs (CID) Pilot Meeting Program, an initiative which aims to further modernize drug development, improve efficiency, and promote innovation. Lilly's proposed program involves a master protocol for the development of novel approaches to the treatment of multiple types of chronic pain, one of the largest unmet medical needs in the United States. ...
Sep 04, 2019 04:15 pm ET
Lilly to Participate in Morgan Stanley Global Healthcare Conference
INDIANAPOLIS, Sept. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 1:00 p.m., Eastern Time. ...
Aug 26, 2019 06:45 am ET
Lilly Receives U.S. FDA Approval for Taltz® (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
INDIANAPOLIS, Aug. 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment of adults with active ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA)....
Aug 23, 2019 02:55 pm ET
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
INDIANAPOLIS, Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019. ...
Aug 22, 2019 08:59 pm ET
Arbitration panel rules in favor of Lilly in complaint filed by Adocia
INDIANAPOLIS, Aug. 22, 2019 /PRNewswire/ -- A Chicago-based arbitration panel has ruled in favor of Eli Lilly and Company (NYSE: LLY) in a claim filed by Adocia S.A. over the companies' prior collaboration on a rapid-acting insulin. The panel of three arbitrators ruled that Lilly acted appropriately regarding Adocia's intellectual property, and while they denied Lilly's smaller counterclaim, ruled that Lilly is not liable for damages....
Aug 19, 2019 04:15 pm ET
Lilly Announces Webcast to Discuss World Conference on Lung Cancer Presentation
INDIANAPOLIS, Aug. 19, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, September 9, 2019 to discuss data presented for its RET-Inhibitor, LOXO-292, at the 20th meeting of the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Barcelona, Spain. Remarks will focus on registrational results from the LIBRETTO-001 trial, a Phase 1/2 trial of LOXO-292 in patients with RET fusion-positive lung cancers. The webcast will begin at 7:00 p.m. Central European Time, or 1:00 p.m. Eastern Time....
Aug 14, 2019 06:45 am ET
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
INDIANAPOLIS, Aug. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is launching an open innovation challenge to encourage individuals and teams across the U.S. to identify and submit pioneering digital health solutions aimed at transforming inflammatory bowel disease (IBD) care. The challenge, "Transforming IBD Care: Better disease monitoring, management, and care for people with inflammatory bowel disease," focuses on innovation in IBD monitoring, condition management or care enhancements. The submission form, including additional details about the challenge's criteria, eligibili...
Aug 13, 2019 06:45 am ET
Lilly Announces Superiority of Taltz® (ixekizumab) versus TREMFYA® (guselkumab) in Delivering Total Skin Clearance at Week 12 in Topline Results from Head-to-Head (IXORA-R) Trial in People Living with
INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 IXORA-R study, which evaluated the efficacy and safety of Taltz versus TREMFYA® (guselkumab) in people living with moderate to severe plaque psoriasis (PsO). The IXORA-R trial is the first completed head-to-head (H2H) trial between an IL-17A inhibitor and an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint. ...
Aug 09, 2019 12:17 pm ET
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Alternate Salt Form Patent Lawsuit
INDIANAPOLIS, Aug. 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit ruled in favor of Lilly, confirming that the Alimta® (pemetrexed for injection) vitamin regimen patent would be infringed by competitors that had stated their intent to market alternative salt forms of pemetrexed prior to the patent's expiration in May 2022....
Aug 08, 2019 09:00 am ET
Lilly Announces Positive Results for Emgality™ (galcanezumab) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
Failure to respond to migraine preventive treatments is a common occurrence;internationally it is estimated that more than 40% of patients who use migraine preventive medications have a history of failure or switching treatments1...
Aug 08, 2019 06:45 am ET
Lilly, Evidation Health and Apple Study Shows Personal Digital Devices May Help in the Identification of Mild Cognitive Impairment and Mild Alzheimer's Disease Dementia
INDIANAPOLIS, Aug. 8, 2019 /PRNewswire/ -- Initial results from a feasibility study conducted by Eli Lilly and Company (NYSE: LLY), Evidation Health, and Apple Inc. (NASDAQ: AAPL) showed that an iPhone, Apple Watch, iPad and the Beddit sleep monitoring device, in combination with digital apps may be able to differentiate people with mild cognitive impairment (MCI) and mild Alzheimer's disease dementia.1 The exploratory results were presented today at the Association for Computing Machinery's KDD conference in Anchorage, and are published on the conference website as one of the top papers of ...
Aug 07, 2019 06:45 am ET
Lilly Announces Leadership Changes in Corporate Business Development, Oncology R&D, and Managed Healthcare Services
INDIANAPOLIS, Aug. 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced several leadership changes in the company's corporate business development, oncology R&D, and managed healthcare services organizations....
Aug 05, 2019 06:45 am ET
Lilly Announces Positive Results for Emgality® (galcanezumab-gnlm) from the CONQUER Study in Patients who Failed Previous Migraine Preventive Treatments
INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment of chronic and episodic migraine in patients with documented previous failures on two to four different standard-of-care migraine preventive medication categories, due to inadequate efficacy or for safety/tolerability reasons.2...
Jul 30, 2019 06:25 am ET
Lilly Reports Second-Quarter 2019 Financial Results, Raises 2019 EPS Guidance
INDIANAPOLIS, July 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2019....
Jul 30, 2019 06:00 am ET
Lilly's Verzenio® (abemaciclib) Significantly Extended Life in Women with HR+, HER2- Advanced Breast Cancer in MONARCH 2
INDIANAPOLIS, July 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Verzenio (abemaciclib) demonstrated a statistically significant improvement in overall survival in the Phase 3 MONARCH 2 clinical trial. These results were from a pre-planned interim analysis and are definitive. MONARCH 2 evaluated Verzenio in combination with fulvestrant for the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer previously treated with endocrine therapy. The study included both...
Jul 24, 2019 11:19 pm ET
BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA
INDIANAPOLIS, July 24, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY) announced today. BAQSIMI is the first and only nasally administered glucagon, and it was designed with severe hypoglycemia rescue in mind. It is compact, portable and ready to use (no reconstitution required) in a single, fixed, 3 mg dose.  ...
Jul 17, 2019 07:00 am ET
AC Immune Initiates Phase 1 Study of ACI-3024 Small Molecule Tau Morphomer™, an Investigational Treatment for Alzheimer’s Disease
AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company, today announced dosing of the first subject in a Phase 1 study of ACI-3024, a first-in-class investigational oral small molecule Tau Morphomer™ inhibitor that...
Jul 13, 2019 06:45 am ET
Lilly Presents New Findings on Stigma Faced by People with Migraine Based on Interim Results from the OVERCOME Observational Study
INDIANAPOLIS, July 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the presentation of data about personal attitudes toward migraine among people without the disease.1 These data are from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study. The findings demonstrate that discriminating attitudes towards people with migraine, unconscious or otherwise, are deep-rooted and advanced by a lack of understanding about the disease.1 They point to a need for greater respect for, and appreciation of, this serious neurologic disease.1 ...
Jul 12, 2019 08:00 am ET
Lilly's OVERCOME Observational Study Reveals Inconsistent and Sub-Optimal Treatment Landscape for Migraine
INDIANAPOLIS, July 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced the upcoming presentation of data highlighting inconsistent and sub-optimal treatment patterns that people living with migraine experience across the U.S. healthcare landscape, specifically related to where they receive care.1 These data are from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study, which collected responses from more than 20,000 people living with migraine. The results showed that people with migraine seek care in a variety of settings, with a sig...
Jul 12, 2019 06:45 am ET
AHS 2019: Post-Hoc Analyses of Phase 3 Pivotal Studies of Emgality® (galcanezumab-gnlm) Show Improvements in Daily Functioning and Reductions in Disability in Patients with Chronic and Episodic Migrai
INDIANAPOLIS, July 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the presentation of post-hoc analyses showing improvements in daily functioning and reductions in disability in patients with chronic and episodic migraine treated with Emgality® (galcanezumab-gnlm) compared to placebo.1 The analyses are based on data from three double-blind, placebo-controlled, Phase 3 pivotal studies of Emgality in chronic (REGAIN) and episodic migraine (EVOLVE-1 & EVOLVE-2).1 The data will be presented today at the 61st Annual Scientific Meeting of the American Headache Socie...
Jul 11, 2019 08:15 am ET
Lilly Announces Changes in Senior Leadership
INDIANAPOLIS, July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced several changes to the company's executive committee.  ...
Jul 11, 2019 06:45 am ET
New England Journal of Medicine Publishes Positive Phase 3 Data for Emgality® (galcanezumab-gnlm) in Episodic Cluster Headache
INDIANAPOLIS, July 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the New England Journal of Medicine published positive Phase 3 study results of Emgality® (galcanezumab-gnlm) for the treatment of episodic cluster headache.1 In this study, Emgality reduced the frequency of weekly cluster headache attacks across Weeks 1 to 3 compared to placebo.1 The U.S. Food and Drug Administration (FDA) approval of Emgality for the treatment of episodic cluster headache in adults in June 2019 was based on these results....
Jul 10, 2019 02:15 pm ET
Lilly Announces Upcoming Presentation of New Data Indicating Rise in Opioid Use for Migraine Treatment
INDIANAPOLIS, July 10, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of data indicating rising rates of opioid use for the treatment of migraine based on results from the OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) study.1 These findings will be presented on Saturday, July 13, 2019, at the 61st Annual Scientific Meeting of the American Headache Society taking place in Philadelphia....
Jul 09, 2019 04:15 pm ET
Lilly Confirms Date and Conference Call for Second-Quarter 2019 Financial Results Announcement
INDIANAPOLIS, July 9, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2019 financial results on Tuesday, July 30, 2019. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance....
May 28, 2019 07:54 am ET
Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics
INDIANAPOLIS, May 28, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a license agreement to acquire the exclusive worldwide rights for CNTX-0290 from Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain. CNTX-0290, is a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist that is currently being studied in Phase 1 clinical testing as a potential non-opioid treatment for chronic pain conditions. ...
May 22, 2019 06:30 am ET
Lilly's Lower-Priced Insulin Now Available
INDIANAPOLIS, May 22, 2019 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) Insulin Lispro Injection is now available for order in pharmacies for people who use Lilly's rapid-acting insulin and need a lower-cost option. Lilly's Insulin Lispro Injection has a 50 percent lower list price than its identical medicine, Humalog® U-100 (insulin lispro injection) and is available in both a vial and KwikPen®. Because they are the same insulin, pharmacists will be able to substitute Insulin Lispro Injection for Humalog. ...
May 21, 2019 01:15 pm ET
Lilly's Mirikizumab Met Primary Endpoint and Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions
INDIANAPOLIS, May 21, 2019 /PRNewswire/ -- In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company (NYSE: LLY) announced new safety and efficacy data for mirikizumab in patients with moderately- to severely active Crohn's disease. Patients treated with mirikizumab in the SERENITY Phase 2 study achieved significant reductions in clinical and endoscopic measures of disease activity at 12 weeks compared to placebo. The maintenance phase of this study is ongoing....
May 16, 2019 04:30 pm ET
Lilly to Participate in UBS Global Healthcare Conference
INDIANAPOLIS, May 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019. Christi Shaw, president of Lilly Bio-Medicines, will participate in a fireside chat at 9:30 a.m., Eastern Time. ...
May 15, 2019 05:00 pm ET
Data Presentations at ASCO 2019 Highlight Lilly's Targeted Approach to Developing Treatments for Patients Living with Cancer
INDIANAPOLIS, May 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that data from a number of studies across the company's oncology product portfolio will be presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, May 31-June 4, 2019. Data from 23 oral presentations and posters underscore Lilly Oncology's focus on making a meaningful difference in the lives of people living with cancer, especially those with hard-to-treat tumor types.  ...
May 15, 2019 06:30 am ET
Lilly to Participate in Bank of America Merrill Lynch Health Care Conference
INDIANAPOLIS, May 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will participate in a fireside chat at 9:20 a.m. PDT (12:20 p.m. EDT). ...
May 13, 2019 06:45 am ET
Lilly's CYRAMZA® (ramucirumab) Becomes First FDA-Approved Biomarker-Driven Therapy in Patients with Hepatocellular Carcinoma
INDIANAPOLIS, May 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10 mg/mL solution), as a single agent, for the treatment of patients with hepatocellular carcinoma (HCC) who have an alpha-fetoprotein (AFP) of ≥400 ng/mL and have been treated with sorafenib. Concurrent with this FDA approval – the fifth for CYRAMZA – the FDA has also removed the boxed warning from the CYRAMZA labeling....
May 08, 2019 06:45 am ET
AAN 2019: Two New Analyses of Lasmiditan Phase 3 Studies Measured Onset of Effect and the Effect of Lasmiditan in Patients with Prior Triptan Experience
INDIANAPOLIS, May 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new data and post-hoc analyses for lasmiditan, an investigational, oral, first-in-class molecule for the acute treatment of migraine, being presented at the Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia from May 4-10, 2019. The presentations include pooled analyses from the Phase 3 SAMURAI and SPARTAN studies. The first analysis, presented on Monday, May 6, reviewed data on the early onset of effect of lasmiditan for several key outcomes. The second analysis, b...
May 06, 2019 02:16 pm ET
Lilly Declares Second-Quarter 2019 Dividend
INDIANAPOLIS, May 6, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.645 per share on outstanding common stock. ...
May 06, 2019 06:45 am ET
AAN 2019: Pooled Analyses of Two Emgality® (galcanezumab-gnlm) Phase 3 Studies Show Reduction in Monthly Migraine Headache Days in Low- and High-Frequency Episodic Migraine Subgroups
INDIANAPOLIS, May 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 and EVOLVE-2 studies. These analyses demonstrate a reduction in monthly migraine headache days with Emgality® (galcanezumab-gnlm) versus placebo in patients with low- and high-frequency episodic migraine.1 Detailed results will be presented in an oral platform presentation (S17.003) at the Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia from May 4-10, 201...
May 02, 2019 06:45 am ET
Lilly to Present New Data at AAN 2019 on Emgality® (galcanezumab-gnlm) and Lasmiditan Reinforcing Breadth of Headache Disorders Portfolio
INDIANAPOLIS, May 2, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present 19 scientific abstracts for Emgality® (galcanezumab-gnlm) and lasmiditan at the 71st Annual Meeting of the American Academy of Neurology (AAN) taking place in Philadelphia from May 4-10, 2019.  Emgality (120 mg) is indicated for the preventive treatment of migraine, Emgality (300 mg) is an investigational drug for the preventive treatment of episodic cluster headache, and lasmiditan is an investigational drug for the acute treatment of migraine, all in adults. ...
Apr 30, 2019 06:25 am ET
Lilly Reports Solid First-Quarter 2019 Financial Results, Updates 2019 Guidance to Reflect Disposition of Elanco Animal Health
INDIANAPOLIS, April 30, 2019  PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2019....
Apr 26, 2019 11:28 am ET
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit
INDIANAPOLIS, April 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Court of Appeals for the Federal Circuit has ruled in the company's favor regarding patentability of the vitamin regimen for Alimta® (pemetrexed for injection). The decision upholds an October 2017 decision by the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (PTO)....
Apr 25, 2019 06:45 am ET
Lilly to Establish an Access Program for Patients as it Prepares to Withdraw Lartruvo from the Global Market
INDIANAPOLIS, April 25, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the company has been working to facilitate the withdrawal of Lartruvo® (olaratumab) from the market for the treatment of advanced soft tissue sarcoma (STS). Lilly's actions to withdraw Lartruvo from the market follow the failure of the Phase 3 ANNOUNCE clinical trial, in which Lartruvo did not improve survival for patients. Lilly is establishing a program to ensure current patients will have access to Lartruvo with limited interruption after it is withdrawn from the market. The program will be...
Apr 22, 2019 10:05 pm ET
Lilly Announces Sale of Legacy Antibiotics Brands and Manufacturing Facility in China
INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor® and Vancocin®, as well as a manufacturing facility in Suzhou, China that produces Ceclor, to Eddingpharm, a China-based specialty pharmaceutical company. ...
Apr 22, 2019 06:45 am ET
Lilly Announces Positive Top-Line Results for COAST-X, a 52-Week Placebo-Controlled Study of Taltz® (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA) in patients who are biologic disease-modifying anti-rheumatic drug (bDMARD)-naïve. These results provide clinical evidence to support a potential role for Taltz in the treatment of nr-axSpA patients. ...
Apr 22, 2019 06:30 am ET
Lilly and Avidity Biosciences Announce Licensing and Research Collaboration
INDIANAPOLIS and LA JOLLA, Calif., April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avidity Biosciences, Inc. today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in immunology and other select indications. ...
Apr 10, 2019 04:30 pm ET
Lilly Confirms Date and Conference Call for First-Quarter 2019 Financial Results Announcement
INDIANAPOLIS, April 10, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2019 financial results on Tuesday, April 30, 2019. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance....
Apr 01, 2019 05:00 am ET
Arteaus Therapeutics Sells Emgality Royalty to Royalty Pharma for $260 Million
NEW YORK, April 1, 2019 /PRNewswire/ -- Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced today that Arteaus has sold its royalty interest on future global net sales of Eli Lilly and Company's (NYSE: LLY) Emgality (galcanezumab), an anti-CGRP antibody for the prevention of migraine, to Royalty Pharma for $260 million....
Mar 26, 2019 04:30 pm ET
Lilly and ImmuNext Announce Licensing and Research Collaboration
INDIANAPOLIS and LEBANON, N.H., March 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ImmuNext, Inc. today announced a global licensing and research collaboration focused on the study of a preclinical novel target that could lead to potential new medicines for autoimmune diseases by regulating immune cell metabolism. ...
Mar 25, 2019 07:40 am ET
Recent Analysis Shows Mastercard, Halliburton, Keysight Technologies, Eli Lilly, Wabash National, and Regeneron Pharmaceuticals Market Influences — Renewed Outlook, Key Drivers of Growth
In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Mastercard Incorporated (NYSE:MA), Halliburton Company (NYSE:HAL), Keysight...
Mar 20, 2019 08:45 am ET
NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology
PLYMOUTH MEETING, Pa. and INDIANAPOLIS, March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Eli Lilly and Company (NYSE: LLY) today announced six projects that aim to improve the delivery of gastric and gastroesophageal junction (GEJ) cancer care in the United States. The quality improvement studies will focus on methods of intervention that can be implemented across a variety of different oncology practice settings. These projects are eligible to receiving funding from Lilly Oncology after completing contract negotiations. Fo...
Mar 13, 2019 08:00 am ET
Lilly Announces Final Results of Elanco Exchange Offer
INDIANAPOLIS, March 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the final results of its offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) previously owned by Lilly, which expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019....
Mar 12, 2019 06:45 am ET
Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Ce
INDIANAPOLIS, March 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RELAY study of CYRAMZA® (ramucirumab) met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant improvement in the time patients lived without their cancer growing or spreading after starting treatment. The Phase 3 global, randomized, double-blind trial is evaluating CYRAMZA in combination with erlotinib, compared to placebo in combination with erlotinib, as a first-line treatment in patients with metastatic non-small cell lung cancer (N...
Mar 11, 2019 09:31 am ET
Option-trading opportunities on Applied Materials, Inc., The Boeing Co., Jd.com Inc., Eli Lilly and Co., and NVIDIA Corp.
NEW YORK, March 11, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMAT, BA, JD, LLY, and NVDA....
Mar 11, 2019 06:45 am ET
Lilly Announces Preliminary Results of Elanco Exchange Offer
INDIANAPOLIS, March 11, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that, based on preliminary results, its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Lilly was oversubscribed. The exchange offer expired at 12:00 midnight, New York City time, at the end of the day on March 8, 2019. Under the terms of the exchange offer, 4.5121 shares of Elanco common stock will be exchanged for each share of Lilly common stock accepted in the exchange offer....
Mar 08, 2019 06:30 am ET
Lilly to Participate in Barclays Global Healthcare Conference
INDIANAPOLIS, March 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific Officer and President of Lilly Research Laboratories, will participate in a fireside chat at 8:30 a.m., Eastern Time. ...
Mar 07, 2019 04:15 pm ET
Lilly to Participate in Cowen Health Care Conference
INDIANAPOLIS, March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019. Joshua Smiley, senior vice president and Lilly's chief financial officer, will participate in a fireside chat at noon, Eastern Time. ...
Mar 07, 2019 05:45 am ET
Lilly Announces Final Exchange Ratio of 4.5121 for Elanco Exchange Offer
INDIANAPOLIS, March 7, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the final exchange ratio for its previously-announced offer for shareholders to exchange their shares of Lilly common stock for shares of Elanco Animal Health Incorporated (NYSE: ELAN) owned by Lilly....
Mar 05, 2019 05:45 am ET
Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults
INDIANAPOLIS, March 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental Biologics License Application (sBLA) for Emgality® (galcanezumab-gnlm) injection for the preventive treatment of episodic cluster headache in adults. Priority Review aims to expedite the review of applications for drugs that, if approved, could potentially represent a significant advancement in treatment for a serious condition. ...
Mar 04, 2019 05:30 am ET
Lilly to Introduce Lower-Priced Insulin
INDIANAPOLIS, March 4, 2019 /PRNewswire/ -- Reinforcing our commitment to lower out-of-pocket costs for people who need insulin, Eli Lilly and Company (NYSE: LLY) today announced we will introduce a lower-priced version of Humalog® (insulin lispro injection 100 units/mL) in the United States -- providing people with diabetes an insulin option that will have a list price 50 percent lower than the current Humalog list price....
Mar 01, 2019 05:45 am ET
Lilly to Present Data Demonstrating Continued Scientific Advancements in Broad Dermatology Portfolio at AAD Annual Meeting
INDIANAPOLIS, March 1, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that it will present data for Taltz® (ixekizumab) and mirikizumab at the American Academy of Dermatology (AAD) annual meeting taking place March 1-5, 2019 in Washington, DC.  ...
Feb 28, 2019 08:31 am ET
Option-trading opportunities on Apple, Eli Lilly, Nike, Planet Fitness, and Weight Watchers
NEW YORK, Feb. 28, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, LLY, NKE, PLNT, and WTW....
Feb 22, 2019 07:30 am ET
New Research Coverage Highlights FedEx, Honeywell International, Nielsen Holdings Plc, Changyou, J.B. Hunt Transport Services, and Eli Lilly — Consolidated Revenues, Company Growth, and Expectations f
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of FedEx Corporation (NYSE:FDX), Honeywell International Inc. (NYSE:HON),...
Feb 20, 2019 08:31 am ET
Option-trading strategies on Freeport-McMoRan, Eli Lilly and Co., Riot Blockchain Inc., Twitter Inc. and Uniti Group Inc.
NEW YORK, Feb. 20, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FCX, LLY, RIOT, TWTR, and UNIT....
Feb 19, 2019 05:45 am ET
Pfizer and Lilly Announce Top-line Results From Phase 3 Study of Tanezumab in Chronic Low Back Pain
NEW YORK and INDIANAPOLIS, Feb. 19, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Eli Lilly and Company (NYSE: LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab in patients with moderate-to-severe chronic low back pain (CLBP). In the study, treatment with tanezumab 10 mg met the primary endpoint, demonstrating a statistically significant improvement in pain at 16 weeks compared to placebo. The tanezumab 5 mg arm demonstrated a numerical improvement in pain, but did not reach statistical significance compared to placebo at the week 16 analysis. Full r...
Feb 15, 2019 02:49 pm ET
Hagens Berman: Judge Denies Insulin Makers’ Motion to Dismiss Class-Action Lawsuit Regarding Skyrocketing Insulin Prices
Today, a federal judge’s opinion has greenlighted a national class-action lawsuit filed against Sanofi, Novo Nordisk and Eli Lilly for their systematic
Feb 15, 2019 08:23 am ET
Lilly Completes Acquisition of Loxo Oncology
INDIANAPOLIS, Feb. 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Loxo Oncology, Inc. (NASDAQ:LOXO). The acquisition broadens the scope of Lilly's oncology portfolio into precision medicines through the addition of a pipeline of highly selective potential medicines for patients with genomically defined cancers....
Feb 14, 2019 03:30 pm ET
Lilly To Participate in Leerink Partners Global Healthcare Conference
INDIANAPOLIS, Feb. 14, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Leerink Partners Global Healthcare Conference on Wednesday, February 27, 2019. Christi Shaw, president of Lilly Bio-Medicines, will participate in a fireside chat at 1:00 p.m., Eastern Time. ...
Feb 14, 2019 05:30 am ET
Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride
RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 14, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority for Tradjenta® (linagliptin) versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3P-MACE)....
Feb 11, 2019 08:31 am ET
Option-trading strategies on Apple, Facebook, General Electric, Eli Lilly, and Vale
NEW YORK, Feb. 11, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, FB, GE, LLY, and VALE....
Feb 08, 2019 12:00 pm ET
Lilly to Participate in Guggenheim Healthcare Talks Idea Forum
INDIANAPOLIS, Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the Guggenheim Healthcare Talks Idea Forum on Thursday, February 14, 2019. Anne White, president of Lilly Oncology, and Levi Garraway, M.D., Ph.D., senior vice president, oncology research and development, will participate in a fireside chat at 1:00 p.m., Eastern Time. ...
Feb 08, 2019 07:45 am ET
New Research Coverage Highlights Eli Lilly, Newell Brands, Novanta, Carrols Restaurant Group, 8x8, and Quanta Services — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Eli Lilly and Company (NYSE:LLY), Newell Brands Inc. (NASDAQ:NWL), Novanta...
Feb 08, 2019 05:45 am ET
Lilly Will Initiate Divestiture of its Remaining Interest in Elanco Animal Health
INDIANAPOLIS, Feb. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced it will initiate an exchange offer today to divest its remaining interest in Elanco Animal Health (NYSE: ELAN)....
Feb 06, 2019 05:25 am ET
Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology
INDIANAPOLIS, Feb. 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the fourth quarter and full year of 2018....
Feb 04, 2019 05:45 am ET
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
INDIANAPOLIS, Feb. 4, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD1 and BREEZE-AD2, two Phase 3 studies evaluating the efficacy and safety of baricitinib monotherapy for the treatment of adult patients with moderate to severe atopic dermatitis (AD). In both investigational trials, compared to patients treated with placebo, a statistically significant proportion of patients treated with baricitinib achieved the primary endpoint at Week 16 defined by the Investigator's Global ...
Feb 01, 2019 06:45 am ET
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
Eli Lilly and Company (NYSE: LLY) (“Lilly”) and Loxo Oncology, Inc. (NASDAQ: LOXO) (“Loxo Oncology”) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in...
Feb 01, 2019 05:45 am ET
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
INDIANAPOLIS and STAMFORD, Conn., Feb. 1, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ("Lilly") and Loxo Oncology, Inc. (NASDAQ: LOXO) ("Loxo Oncology") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), in connection with Lilly's previously-announced tender offer to acquire all outstanding shares of Loxo Oncology for a purchase price of $235.00 per share in cash (the "Offer Price"), or approximately $8.0 billion. ...
Jan 31, 2019 05:45 am ET
FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer
INDIANAPOLIS, Jan. 31, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a new indication for ALIMTA® (pemetrexed for injection) in combination with KEYTRUDA® (pembrolizumab), developed and marketed by Merck (known as MSD outside the U.S. and Canada), and platinum chemotherapy for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. This indication is approved based on data from Merck's Phase 3 KEYNOTE-18...
Jan 30, 2019 02:15 pm ET
Lilly Revises Date for Fourth-Quarter 2018 Financial Results Announcement
INDIANAPOLIS, Jan. 30, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has revised the date for its fourth-quarter and full-year 2018 financial results announcement. The company will now announce results on Wednesday, February 6, 2019, one week earlier than previously scheduled. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance....
Jan 29, 2019 06:30 am ET
Pfizer and Lilly Announce Top-Line Results From Second Phase 3 Study of Tanezumab in Osteoarthritis Pain
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain. The tanezumab 5 mg treatment arm met all three co-primary endpoints at 24 weeks, demonstrating a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA compared to those receiving placebo. The tanezumab 2.5 mg treatment arm met two of the three protocol-defined co
Jan 23, 2019 07:00 am ET
Government Employees Affected by Federal Shutdown Encouraged to Contact Lilly Diabetes Solution Center to Access Insulin
INDIANAPOLIS, Jan. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) is encouraging government employees affected by the partial government shutdown to call the Lilly Diabetes Solution Center and check whether they are receiving all eligible discounts to lower the out-of-pocket costs for their Lilly insulin. The Solution Center may be able to provide discounts based upon the personal circumstances of each person who calls. Any government employee who is not being paid because of the shutdown can talk to a live U.S.-based Lilly representative to learn about options available to them ...
Jan 21, 2019 03:15 pm ET
Lilly Confirms Date and Conference Call for Fourth-Quarter 2018 Financial Results Announcement
INDIANAPOLIS, Jan. 21, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2018 financial results on Wednesday, February 13, 2019. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance....
Jan 18, 2019 06:02 pm ET
Lilly Phase 3 REACH-2 Trial Data Published in The Lancet Oncology Shows Improvement in Overall Survival with CYRAMZA® (ramucirumab) in Second-Line AFP-High Hepatocellular Carcinoma Patients
INDIANAPOLIS, Jan. 18, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that results from the global Phase 3 REACH-2 study of CYRAMZA® (ramucirumab) as a single agent in the second-line treatment of people with AFP-High (alpha-fetoprotein ≥400 ng/mL) hepatocellular carcinoma (HCC) were published online today in The Lancet Oncology. Data from REACH-2 are also being presented today at the 2019 Gastrointestinal Cancers Symposium in San Francisco. HCC is also known as liver cancer, which is a leading cause of cancer-related death worldwide.1 In the U.S., liver cancer is one of th...
Jan 18, 2019 05:45 am ET
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®
INDIANAPOLIS, Jan. 18, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today reported that the results of ANNOUNCE, the Phase 3 study of LARTRUVO® (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS), did not confirm the clinical benefit of LARTRUVO in combination with doxorubicin as compared to doxorubicin, a standard of care treatment. Specifically, the study did not meet the primary endpoints of overall survival (OS) in the full study population or in the leiomyosarcoma (LMS) sub-population; there was no difference in survi...
Jan 15, 2019 04:16 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Loxo Oncology, Inc. (“Loxo Oncology” or the “Company”) (NASDAQGM: LOXO) stock prior to January 7, 2019. You are hereby notified that...
Jan 09, 2019 11:56 am ET
MERGER ALERT – BDMS, LOXO and MB: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Birner Dental Management Services, Inc....
Jan 09, 2019 07:25 am ET
Report: Exploring Fundamental Drivers Behind Virtusa, Eli Lilly, Cree, NewJersey Resources, Getty Realty, and PennantPark Investment — New Horizons, Emerging Trends, and Upcoming Developments
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtusa Corporation (NASDAQ:VRTU), Eli Lilly and Company (NYSE:LLY), Cree,...
Jan 08, 2019 02:12 pm ET
WEISSLAW LLP: Loxo Oncology, Inc. Acquisition May Not Be In The Best Interests of LOXO Shareholders
NEW YORK, Jan. 8, 2019 /PRNewswire/ -- WeissLaw LLP  is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Loxo Oncology, Inc. ("LOXO" or the "Company") (NASDAQ: LOXO) in connection with the proposed acquisition of the Company by Eli Lilly Company (NYSE: LLY) ("LLY").  Under the terms of the acquisition agreement, shareholders will be entitled to receive $235.00 in cash for each LOXO share they own.  ...
Jan 07, 2019 07:38 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Loxo Oncology, Inc. (LOXO) on Behalf of Stockholders and Encourages LOXO Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Loxo Oncology, Inc. (NASDAQ: LOXO) on behalf of stockholders concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY)....
Jan 07, 2019 04:12 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Loxo Oncology, Inc.
NEW YORK, Jan. 7, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Loxo Oncology, Inc. (NASDAQ: LOXO) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by Eli Lilly and Company (NYSE: LLY). Stockholders will receive $235.00 for each share of Loxo Oncology, Inc. stock that they hold. The transaction is valued at approximately $8 billion and is expected to close by the end of the first quarter of 2019....
Jan 07, 2019 03:04 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Loxo Oncology, Inc. to Eli Lilly and Company is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Loxo Oncology, Inc. (“Loxo Oncology” or the “Company”) (NASDAQGM: LOXO) stock prior to January 7, 2019. You are hereby notified that...
Jan 07, 2019 10:00 am ET
Bigfoot Biomedical Announces Next Step for Connected Insulin Injection System
Bigfoot Biomedical, Inc., a diabetes company using artificial intelligence to develop solutions for optimizing the dosing and delivery of insulin, today announced a non-exclusive cooperation agreement with Eli Lilly and Company (NYSE: LLY) to support integration of Lilly’s insulin products into Bigfoot’s systems currently in development.
Jan 07, 2019 06:30 am ET
Lilly Announces Agreement To Acquire Loxo Oncology
Eli Lilly and Company (NYSE: LLY) and Loxo Oncology, Inc. (NASDAQ: LOXO) today announced a definitive agreement for Lilly to acquire Loxo Oncology for $235.00 per share in cash, or approximately $8.0 billion. Loxo Oncology is a biopharmaceutical...
Jan 07, 2019 05:30 am ET
Lilly Announces Agreement To Acquire Loxo Oncology
INDIANAPOLIS and STAMFORD, Conn., Jan. 7, 2019 /PRNewswire/ -- ...
Jan 03, 2019 03:30 pm ET
Lilly to Participate in J.P. Morgan Healthcare Conference
INDIANAPOLIS, Jan. 3, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Tuesday, January 8, 2019. David A. Ricks, Lilly's chairman and chief executive officer, will participate in a fireside chat from 6:00 p.m. to 6:25 p.m. Eastern time. ...
Dec 19, 2018 05:25 am ET
Lilly Announces 15 Percent Dividend Increase
INDIANAPOLIS, Dec. 19, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2019 will be $0.645 per share on outstanding common stock. This raises the annual indicated rate to $2.58 per share.  ...
Dec 18, 2018 04:15 pm ET
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for Aduro’s cGAS-STING Pathway Inhibitor program for the research and development of novel...
Dec 18, 2018 03:15 pm ET
Lilly and Aduro Biotech Announce Research Collaboration and License Agreement to Develop Novel Immunotherapies
INDIANAPOLIS and BERKLEY, Calif., Dec. 18, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Aduro Biotech, Inc. (NASDAQ: ADRO) today announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research and development of novel immunotherapies for autoimmune and other inflammatory diseases. ...
Dec 18, 2018 05:45 am ET
Lilly announces publication of analyses showing benefit of the addition of Verzenio® (abemaciclib) in multiple subgroups of patients with advanced breast cancer identified as having a more concerning
INDIANAPOLIS, Dec. 18, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced npj Breast Cancer published results from exploratory subgroup analyses of the MONARCH 2 and MONARCH 3 trials reinforcing the clinical benefit of Verzenio® (abemaciclib) plus endocrine therapy in the treatment of women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. The analyses demonstrate that while the benefit of the addition of Verzenio was seen across all patient subgroups, consistent with the individual study ...
Dec 17, 2018 05:45 am ET
Lilly Announces Positive Top-Line Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
INDIANAPOLIS, Dec. 17, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz® (ixekizumab) met the primary and all major secondary endpoints in the Phase 3b/4 SPIRIT-H2H study, which evaluated the efficacy and safety of Taltz versus Humira® (adalimumab) in patients with active psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drug (DMARD)-naive. The SPIRIT-H2H trial is the first completed large head-to-head (H2H) superiority study in active PsA. This open-label, randomized, controlled trial is the first and only H2H study that utilizes on-labe...
Dec 14, 2018 02:30 pm ET
Lilly to Acquire Pre-Clinical Pain Program from Hydra Biosciences
INDIANAPOLIS, Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced an agreement with Hydra Biosciences to acquire all assets related to  Hydra's pre-clinical program of TRPA1 antagonists, part of the Transient Receptor Potential (TRP) family of ion channels, that is currently being studied for the potential treatment of chronic pain syndromes....
Dec 14, 2018 05:45 am ET
Lilly and Evidation Health Expand Collaboration to Analyze Data from Smartphones and Connected Sensors
INDIANAPOLIS and SAN MATEO, Calif., Dec. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Evidation Health, a health and measurement company that helps innovative life sciences and health care companies understand how everyday behavior and health interact, announced today that they have expanded their collaboration with a multi-year agreement to provide Lilly with global access to Evidation's Andromeda data platform....
Dec 13, 2018 05:45 am ET
FDA Grants Fast Track Designation to the Baricitinib Development Program for the Treatment of Systemic Lupus Erythematosus (SLE)
INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to baricitinib, which is being studied for the treatment of systemic lupus erythematosus (SLE). The Fast Track designation process aims to facilitate the development and expedite the review of new medicines that treat serious conditions and fill unmet medical needs, with the goal of delivering potentially important therapies to patients sooner. ...
Dec 13, 2018 05:30 am ET
Boehringer Ingelheim and Lilly Partner with Duke Clinical Research Institute to Advance Multidisciplinary Care for People with Type 2 Diabetes and Cardiovascular Disease
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 13, 2018 /PRNewswire/ -- The Duke Clinical Research Institute (DCRI) is leading a new clinical study to optimize care for people with type 2 diabetes and cardiovascular disease through evaluation of a multidisciplinary approach at cardiology clinics across the U.S. The research program, COORDINATE-Diabetes (COOrdinating CaRDIology CliNics RAndomized Trial of Interventions to Improve OutcomEs), will be funded by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY)....
Dec 12, 2018 06:30 am ET
AC Immune and Lilly Announce License and Collaboration Agreement
AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE:LLY) today announced that the two companies have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. The collaboration combines AC Immune’s proprietary MorphomerTM platform technology with Lilly’s clinical development expertise and commercial capabilities in central nervous system disorders. The collaboration will focus prima
Dec 12, 2018 05:00 am ET
Lilly and AC Immune Announce License and Collaboration Agreement
INDIANAPOLIS and LAUSANNE, Switzerland, Dec. 12, 2018 /PRNewswire/ --...
Dec 03, 2018 09:15 am ET
NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment
PLYMOUTH MEETING, Pa. and INDIANAPOLIS, Dec. 3, 2018 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) announces plans to solicit and oversee research projects that evaluate cyclin dependent kinase (CDK)4 & 6 inhibitors in the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and underlying mechanisms of resistance. Research funding will be provided by a $2 million grant from Eli Lilly and Company (NYSE: LLY)....
Dec 03, 2018 07:40 am ET
Investor Expectations to Drive Momentum within Virtu Financial, Fate Therapeutics, Tandem Diabetes Care, Eli Lilly, Griffon, and Coherus BioSciences — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Virtu Financial, Inc. (NASDAQ:VIRT), Fate Therapeutics, Inc....
Nov 29, 2018 05:45 am ET
Lilly to Present Clinical Data for Verzenio® (abemaciclib) and Real-World Evidence across HR+, HER2- Metastatic Breast Cancer at 2018 SABCS
INDIANAPOLIS, Nov. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of clinical data at the 2018 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 4-8, 2018 on the safety and efficacy of Verzenio® (abemaciclib) in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer and real-world evidence studies that evaluated the heterogeneity of treatment outcomes among patients with metastatic breast cancer. ...
Nov 27, 2018 05:30 am ET
Lilly to Announce 2019 Financial Guidance, Highlight Late-Stage Pipeline Opportunities and Discuss Commercial Performance at Upcoming Investment Community Meeting
INDIANAPOLIS, Nov. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that it will host a meeting for the investment community on Wednesday, December 19, 2018, from 9:00 a.m. (EST) until approximately 12:00 p.m. ...
Nov 26, 2018 01:34 pm ET
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 26, 2018 /PRNewswire/ -- A new Expert Consensus Decision Pathway issued by the American College of Cardiology (ACC) recommends Jardiance® (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. The recommendation, part of the ACC's first Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in adults with type 2 diabetes and atherosclerotic cardiovascular disease, was released today and pu...
Nov 14, 2018 05:45 am ET
Lilly Submits New Drug Application to the FDA for Lasmiditan for Acute Treatment of Migraine, Receives Breakthrough Therapy Designation for Emgality™ (galcanezumab-gnlm) for Prevention of Episodic Clu
INDIANAPOLIS, Nov. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute treatment of migraine with or without aura in adults. ...
Nov 08, 2018 03:30 pm ET
Lilly to Participate in Credit Suisse 27th Annual Healthcare Conference
INDIANAPOLIS, Nov. 8, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Credit Suisse 27th Annual Healthcare Conference on Tuesday, November 13, 2018. Enrique Conterno, senior vice president of Lilly and president of Lilly Diabetes and Lilly USA, will participate in a fireside chat at 3:40 p.m., Eastern Time. ...
Nov 06, 2018 05:25 am ET
Lilly Delivers Solid Third-Quarter 2018 Results, Revises EPS Guidance
INDIANAPOLIS, Nov. 6, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2018....
Nov 05, 2018 03:30 pm ET
Lilly and NextCure Announce Collaboration to Discover and Develop Novel Immuno-Oncology Medicines
INDIANAPOLIS and BELTSVILLE, Md., Nov. 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and NextCure, Inc. today announced a multi-year collaboration focused on the discovery and development of immuno-oncology therapies. The collaboration seeks to discover novel cancer targets utilizing NextCure's proprietary FIND-IO™ platform. ...
Nov 05, 2018 10:20 am ET
Nov 05, 2018 05:45 am ET
Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes
INDIANAPOLIS, Nov. 5, 2018 /PRNewswire/ -- Trulicity® (dulaglutide) significantly reduced major adverse cardiovascular events (MACE), a composite endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke, meeting the primary efficacy objective in the precedent-setting REWIND trial. Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity is the first type 2 diabetes medicine to demonstrate superiority in the reduction of MACE events in a clinical trial that included a majority of participants who did not have established CV disease....
Nov 05, 2018 05:30 am ET
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabe
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 5, 2018 /PRNewswire/ -- Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed Jardiance® was associated with a 44 percent relative risk reduction in hospitalization for heart failure (HHF) compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in routine clinical practice in the U.S. The EMPRISE analysis of data from approximately 35,000 people with type 2 diabetes between August 2014 and September 2016 will be presented at the American Heart Association® (AHA) Scientific Sessions 2018 in Chicag...
Oct 29, 2018 06:00 am ET
Lilly and Dicerna Announce RNAi Licensing and Research Collaboration
INDIANAPOLIS and CAMBRIDGE, Mass., Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medicines in the areas of cardio-metabolic disease, neurodegeneration and pain. The companies will utilize Dicerna's proprietary GalXC™ RNAi technology platform to progress new drug targets toward clinical development and commercialization. In addition, the partners will collaborate to move beyond the current techni...
Oct 23, 2018 06:40 pm ET
Complete Results from First Study in Ongoing Phase 3 Program for Tanezumab Demonstrated Significant Improvement in Pain and Function in Osteoarthritis Patients
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced complete results from a Phase 3 study evaluating the efficacy and safety of subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, in patients with osteoarthritis (OA) pain treated for 16 weeks. The study met all three co-primary efficacy endpoints, demonstrating that among patients with moderate-to-severe OA pain of the knee or hip, both dosing regimens of tanezumab were associated with a statistically significant improvement
Oct 23, 2018 08:00 am ET
Investor Expectations to Drive Momentum within Navios Maritime Partners LP, Alliance Data, Eli Lilly, CONVERGEONE HLD, Atkore International Group, and NantKwest — Discovering Underlying Factors of Inf
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Navios Maritime Partners LP (NYSE:NMM), Alliance Data Systems Corporation...
Oct 21, 2018 06:30 pm ET
ACR 2018: Lilly Shares Updated Safety Analysis of OLUMIANT® (baricitinib) in Patients with Moderately-to-Severely Active Rheumatoid Arthritis
INDIANAPOLIS, Oct. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today findings from an updated integrated safety analysis of OLUMIANT® (baricitinib) based on an ongoing long-term extension (LTE) study of rheumatoid arthritis (RA) patients treated up to six years. The analysis provides further support for the characterization of OLUMIANT's safety profile, and was shared as an oral presentation today at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting in Chicago, Illin...
Oct 16, 2018 06:45 am ET
Karen Walker Elected to Lilly Board of Directors
INDIANAPOLIS, Oct. 16, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Karen Walker as a new member, effective December 1, 2018. As a member of Lilly's board, she will serve on both the Audit Committee and the Public Policy and Compliance Committee. ...
Oct 15, 2018 01:57 pm ET
Lilly Declares Fourth-Quarter 2018 Dividend
INDIANAPOLIS, Oct. 15, 2018 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2018 of $0.5625 per share on outstanding common stock. ...
Oct 15, 2018 06:45 am ET
New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting
INDIANAPOLIS, Oct. 15, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting taking place Oct. 19-24, 2018, in Chicago. ...
Oct 12, 2018 06:45 am ET
Lilly and Metastatic Breast Cancer Advocates Launch Thriver Movement to Elevate Understanding of the Daily Impact of the Disease, Encourage Public to do More for MBC
INDIANAPOLIS, Oct. 12, 2018 /PRNewswire/ -- Results from a new national, multi-stakeholder survey commissioned by Eli Lilly and Company (NYSE: LLY) reveal that metastatic breast cancer (MBC) places a significant daily strain on those living with the incurable disease. People with MBC who participated in the survey reported spending nearly half their time each week (47%) on things related to their cancer. In addition:...
Oct 10, 2018 06:30 am ET
New analysis estimates the positive impact of Jardiance® on life expectancy in adults with type 2 diabetes and established cardiovascular disease
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 10, 2018 /PRNewswire/ -- Novel results based on data from the landmark EMPA-REG OUTCOME® trial were published in the journal Circulation which suggest that treatment with Jardiance® positively impacts life expectancy in adults with type 2 diabetes and established cardiovascular disease, Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today. Using actuarial methods*, and assuming that the demonstrated beneficial effects of Jardiance remain consistent with long-term use, Jardiance was estimated to extend life expectancy by 1 to 4.5 ...
Oct 09, 2018 05:02 pm ET
Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
TORONTO, Oct. 9, 2018 /CNW/ - Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and clinically meaningful blood sugar reduction and weight loss in people with type 2 diabetes. The six-month data – showing average HbA1c reductions of up to 2.4 percentage points and an average weight reduction up to 11.3 kg (12.7 percent) – were presented today at the 54th Annual Meeting of the European Association for the Study of Diabetes in Berlin and simultaneously published in The Lancet.1...
Oct 08, 2018 06:05 pm ET
Lilly to Present New Data From Oncology Portfolio at ESMO 2018 Congress, Showcasing Patient-Centric Advances in Cancer Care
INDIANAPOLIS, Oct. 8, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data from its clinical development program at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, October 19-23. Data presented showcase how Lilly is taking a global, patient-centric research approach to drive advances in cancer care. Data include presentations on abemaciclib, pemetrexed and ramucirumab, as well as investigational compound pegilodecakin – used as a single agent and in combination with chemotherapy and with checkpoint inhibitor therapy – across multiple...
Oct 04, 2018 11:15 am ET
Boehringer Ingelheim and Lilly present full results of Tradjenta®'s CARMELINA® cardiovascular outcome trial
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Tradjenta® on cardiovascular safety and kidney outcomes in adults with type 2 diabetes at high risk for heart and/or kidney disease. The study met its primary endpoint, with Tradjenta demonstrating a similar cardiovascular safety profile compared with placebo when added to standard of care. The overall safety profile of Tradjenta in the trial, includin...
Oct 04, 2018 06:30 am ET
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today that empagliflozin met the primary efficacy endpoint, defined as a change from baseline in A1C versus placebo after 26 weeks of treatment, for all doses investigated (2.5, 10 and 25 mg) in the Empagliflozin as Adjunctive to inSulin thErapy (EASE) Phase III program in adults with type 1 diabetes. The EASE program results were published online in Diabetes Care ahead of print and presented at the 54th EASD Annual Congress in Berlin today. Empagliflozin is c...
Oct 04, 2018 06:00 am ET
Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes
INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/ -- Results from a phase 2b clinical trial of Eli Lilly and Company's (NYSE: LLY) dual GIP and GLP-1 receptor agonist (GIP/GLP-1 RA, LY3298176) showed strong and clinically meaningful blood sugar reduction and weight loss in people with type 2 diabetes. The six-month data — showing average HbA1c reductions of up to 2.4 percentage points and an average weight reduction up to 11.3 kg (12.7 percent) – were presented today at the 54th Annual Meeting of the European Association for the Study of Diabetes in Berlin and simultaneously published in The Lancet.1...
Oct 03, 2018 03:00 pm ET
Lilly Confirms Date and Conference Call for Third-Quarter 2018 Financial Results Announcement
INDIANAPOLIS, Oct. 3, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the third quarter of 2018 on Tuesday, November 6, 2018. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance....
Oct 02, 2018 06:00 am ET
Results from Two Phase 3 Studies Show Lilly's Ultra Rapid Lispro (URLi) Met Primary Efficacy Endpoint in People with Type 1 and Type 2 Diabetes
INDIANAPOLIS, Oct. 2, 2018 /PRNewswire/ -- Readouts from two phase 3 clinical trials demonstrated that Eli Lilly and Company's (NYSE: LLY) Ultra Rapid Lispro (URLi) met the primary efficacy endpoint of non-inferior A1C reduction from baseline compared to Humalog® (insulin lispro) and also demonstrated significantly improved post-meal glucose control in people with type 1 and type 2 diabetes. ...
Sep 27, 2018 07:52 pm ET
Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults
INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Emgality™ (galcanezumab-gnlm) 120 mg injection for the preventive treatment of migraine in adults.1 Emgality offers a once-monthly, self-administered, subcutaneous injection.1 Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.1...
Sep 26, 2018 07:00 pm ET
Chugai and Lilly Enter into a License Agreement for Oral GLP-1 Agonist, OWL833
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519, Chugai) and Eli Lilly and Company
Sep 24, 2018 05:36 pm ET
Elanco Animal Health Incorporated Announces IPO Closing
Elanco Animal Health Incorporated today announced the closing of its previously announced initial public offering (“IPO”) of 62.9 million shares of its common stock at a price to the public of $24.00 per share. In connection with the IPO, the underwriters exercised in full their option to purchase an additional 9.435 million shares of common stock at the price to the public less underwriting discounts, bringing the total IPO size to 72.335 million shares. The shares began trading on the New York Stock Exchange on September 20, 2018, under the ti
Sep 24, 2018 07:45 am ET
Elanco Announces Full Exercise of Additional Stock, Sets Date for Q3 Earnings
Elanco Animal Health Incorporated (NYSE:ELAN) announced the underwriters of its initial public offering (IPO) have fully exercised their option to purchase an additional 9.435 million shares at the initial public offering price of $24.00 per share, less underwriting discounts, bringing the total IPO size to 72.335 million shares.
Sep 21, 2018 07:46 am ET
Lilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adults
INDIANAPOLIS, Sept. 21, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Emgality™ (galcanezumab) for the prophylaxis of migraine in adults who have at least four migraine days per month....
Sep 19, 2018 05:12 pm ET
Elanco Announces Pricing of Initial Public Offering
Elanco Animal Health Incorporated, a subsidiary of Eli Lilly and Company (NYSE:LLY), announced today the pricing of its initial public offering (IPO) of 62.9 million shares of its common stock at a price to the public of $24.00 per share. The shares are expected to begin trading on the New York Stock Exchange (NYSE) on September 20, 2018 under the ticker symbol “ELAN.” The offering is expected to close on September 24, 2018, subject to customary closing conditions.
Sep 13, 2018 05:01 pm ET
New Lilly Diabetes Center of Excellence Established at the Indiana Bioscience Research Institute
INDIANAPOLIS, Sept. 13, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and the Indiana Bioscience Research Institute (IBRI), in collaboration with Indiana University School of Medicine, have created the Lilly Diabetes Center of Excellence (LDCE), which aims to establish a nexus of strategically aligned basic diabetes research operations in Indianapolis. ...
Sep 12, 2018 09:05 am ET
NCCN and Lilly Support Quality Improvements for Gastric Cancer Care
FORT WASHINGTON, Pa. and INDIANAPOLIS, Sept. 12, 2018 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Eli Lilly and Company (NYSE: LLY) are collaborating to seek proposals for improving care for gastric and gastroesophageal junction (GEJ) cancer patients in the United States. Healthcare institutions, professional organizations, advocacy groups, and other organizations working to improve the quality of care for this patient population are invited to apply. ...
Sep 10, 2018 11:54 am ET
Lilly to Showcase New Data at the 27th European Academy of Dermatology and Venereology (EADV) Congress, Furthering Innovation for Patients with Complex Dermatological Conditions
INDIANAPOLIS, Sept. 10, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 27th annual European Academy of Dermatology and Venereology (EADV) Congress taking place Sep. 12-16, 2018, in Paris, France. The broad range of research revealed through these abstracts demonstrates the company's strategic approach to advancing treatment for serious dermatological conditions through new medicines, patient-focused research and clinical tools....
Sep 10, 2018 09:00 am ET
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz® and Tremfya® in Patients with Moderate-to-Severe Plaque Psoriasis
INDIANAPOLIS, Sept. 10, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the initiation of the IXORA-R head-to-head (H2H) clinical trial, designed to evaluate superiority between Taltz® (ixekizumab) and Tremfya® (guselkumab) in adult patients with moderate-to-severe plaque psoriasis. The IXORA-R study will be the first H2H trial between an IL-17 and IL-23 using the Psoriasis Area Severity Index (PASI) 100 score as the primary endpoint. ...
Sep 06, 2018 07:00 am ET
Lilly Announces Webcast to Discuss EASD Presentations
INDIANAPOLIS, Sept. 6, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Thursday, October 4, 2018 to discuss the company's presentations at the 54th annual meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. Remarks will focus primarily on data from the Phase 2b study of LY3298176, a GIP and GLP-1 dual receptor agonist. The webcast will begin at 7 p.m. Central European Time, or 1 p.m. Eastern Time....
Sep 06, 2018 06:53 am ET
Elanco Announces Launch of IPO Roadshow
GREENFIELD, Ind., Sept. 6, 2018 /PRNewswire/ -- Elanco Animal Health Incorporated, a subsidiary of Eli Lilly and Company (NYSE:LLY), today announced it has launched a roadshow for the initial public offering (IPO) of its common stock. ...
Sep 05, 2018 02:00 pm ET
Lilly Announces Positive Phase 3 Results in Study of Flortaucipir PET Imaging Agent
INDIANAPOLIS, Sept. 5, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced that a Phase 3 study of flortaucipir F 18, a Positron Emission Tomography (PET) imaging agent, met its two primary endpoints, defined as predicting brain tau pathology and predicting Alzheimer's disease diagnosis. ...
Aug 30, 2018 05:00 pm ET
Anne White Promoted to President of Lilly Oncology
INDIANAPOLIS, Aug. 30, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that Anne White has been promoted to senior vice president of Lilly and president of Lilly Oncology effective September 1, 2018. She will become a member of Lilly's executive committee, reporting directly to chairman and chief executive offer, David A. Ricks. ...
Aug 27, 2018 04:30 pm ET
Lilly to Participate in Morgan Stanley Global Healthcare Conference
INDIANAPOLIS, Aug. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the Morgan Stanley Global Healthcare Conference on Wednesday, September 12, 2018. Joshua Smiley, senior vice president and Lilly's chief financial officer, will participate in a fireside chat at 1:40 p.m., Eastern Time. ...
Aug 27, 2018 02:21 pm ET
Rimidi Announces Addition of Jim Clifford as Vice President of Strategic Sales
ATLANTA, Aug. 27, 2018 /PRNewswire/ -- Rimidi, a digital health company that provides software and clinical analytics for chronic disease management, today announced that Jim Clifford has joined the company as Vice President of Strategic Sales.  ...
Aug 14, 2018 09:25 pm ET
Elanco Animal Health Announces Pricing of $2.0 Billion of Senior Notes
INDIANAPOLIS, Aug. 14, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health Incorporated, has priced a private offering of $2.0 billion of senior notes (the "Offering"), consisting of $500 million aggregate principal amount of 3.912 percent senior notes due August 27, 2021; $750 million aggregate principal amount of 4.272 percent senior notes due August 28, 2023; and $750 million aggregate principal amount of 4.900 percent senior notes due August 28, 2028....
Aug 02, 2018 05:40 pm ET
Elanco Animal Health Files IPO Registration Statement
INDIANAPOLIS, Aug. 2, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that its subsidiary, Elanco Animal Health, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) for an initial public offering (IPO) of common stock....
Aug 01, 2018 09:00 am ET
Lilly Diabetes Solution Center Now Open to Help People with Insulin Affordability
INDIANAPOLIS, Aug. 1, 2018 /PRNewswire/ -- The Lilly Diabetes Solution Center, a new patient-focused helpline with representatives who will identify personalized solutions to address insulin affordability, is now available to residents in the U.S. and all U.S. territories. Beginning today, this suite of solutions will provide many options – some being offered for the first time – that can significantly lower and cap high monthly out-of-pocket costs for some people who use Lilly insulins such as Humalog® (insulin lispro) and Humulin® (insulin human injection). Dedicated representatives will r...
Jul 30, 2018 06:45 am ET
Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute
INDIANAPOLIS, July 30, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a three-year extension of its cancer research collaboration with Dana-Farber Cancer Institute. Since 2015, scientists from Lilly and Dana-Farber have been working together on pre-clinical and clinical studies, molecular analyses of patient samples and the design and conduct of clinical trials to help advance cancer care....
Jul 27, 2018 08:00 am ET
New Research: Key Drivers of Growth for ICU Medical, A. Schulman, Verso, Eli Lilly, Spectrum Pharmaceuticals, and Intuit — Factors of Influence, Major Initiatives and Sustained Production
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ICU Medical, Inc. (NASDAQ:ICUI), A. Schulman, Inc. (NASDAQ:SHLM), Verso...
Jul 24, 2018 06:25 am ET
Lilly Delivers Strong Second-Quarter 2018 Results, Revises EPS Guidance
INDIANAPOLIS, July 24, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the second quarter of 2018....
Jul 24, 2018 06:20 am ET
Lilly to Separate Elanco Animal Health with Initial Public Offering
INDIANAPOLIS, July 24, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the company has completed its strategic review of Elanco Animal Health, and will file a registration statement in the coming weeks with the U.S. Securities and Exchange Commission (SEC) for a potential initial public offering (IPO) of a minority ownership stake in Elanco as a separate company....
Jul 20, 2018 09:30 am ET
Highlights from Lilly's Alzheimer's Disease Pipeline at the Alzheimer's Association International Conference® 2018 (AAIC® 2018)
INDIANAPOLIS, July 20, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that new results from a number of studies across the company's Alzheimer's disease pipeline will be presented at the Alzheimer's Association International Conference (AAIC) in Chicago, July 22-26, 2018. Nearly 30 oral and poster presentations will underscore Lilly's focus on making a meaningful difference in the lives of people living with Alzheimer's through clinical development and collaboration. ...
Jul 19, 2018 06:30 pm ET
Study Published in The Lancet Shows Benefit of Baricitinib 4 mg for the Treatment of Systemic Lupus Erythematosus (SLE)
INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that results of a global systemic lupus erythematosus (SLE) Phase 2 study for baricitinib were published by The Lancet. The study, the first completed Phase 2 study of a JAK inhibitor in SLE, showed that a statistically significant proportion of patients treated with 4 mg of baricitinib achieved resolution of their SLE-related arthritis or rash compared to placebo at week 24, the primary endpoint for the trial. ...
Jul 19, 2018 08:00 am ET
Boehringer Ingelheim and Lilly announce Tradjenta's CARMELINA® cardiovascular outcome trial meets primary endpoint
RIDGEFIELD, Conn. and INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- CARMELINA® (CArdiovascular safety and Renal Microvascular outcomE with LINAgliptin in patients with type 2 diabetes at high vascular risk) met its primary endpoint, defined as time to first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke (3-point MACE), with Tradjenta® demonstrating similar cardiovascular safety compared with placebo. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced the positive top-line results from the trial, which evaluated the impact of treatment ...
Jul 19, 2018 06:45 am ET
Lilly's Once-Weekly Trulicity® (dulaglutide) Label Updated to Include Data Showing Benefits for Adults with Type 2 Diabetes and Chronic Kidney Disease
INDIANAPOLIS, July 19, 2018 /PRNewswire/ -- The U.S. label for Eli Lilly and Company's (NYSE: LLY) once-weekly Trulicity® (dulaglutide) is updated to show the medicine's safety and efficacy in people with type 2 diabetes who have moderate to severe chronic kidney disease (CKD). The label now includes data from the AWARD-7 clinical trial, which showed that people treated with Trulicity 1.5 mg or 0.75 mg in combination with mealtime insulin lispro achieved similar glycemic control with weight loss, compared to those treated with traditional basal-bolus insulin.1 Trulicity is a once-weekly gluc...
Jul 18, 2018 06:45 am ET
Pfizer And Lilly Announce Positive Top-Line Results From Phase 3 Trial Of Tanezumab For The Treatment Of Osteoarthritis (OA) Pain
Pfizer Inc.(NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that a 16-week Phase 3 study in patients with osteoarthritis (OA) pain evaluating subcutaneous administration of tanezumab, an investigational humanized monoclonal antibody, met all three co-primary endpoints. The study demonstrated that patients who received two doses of tanezumab separated by eight weeks experienced a statistically significant improvement in pain, physical function and the patients’ overall assessment of their OA, compared to those receiving placebo.
Jul 12, 2018 06:45 am ET
New Lilly Diabetes helpline to Assist People Seeking Solutions to Insulin Affordability
INDIANAPOLIS, July 12, 2018 /PRNewswire/ -- Starting August 1, a new dedicated helpline called the Lilly Diabetes Solution Center will assist people who need help paying for their insulin – such as those with lower incomes, the uninsured, and people in the deductible phase of their high-deductible insurance plans, Eli Lilly and Company (NYSE: LLY) announced today. A customized suite of solutions for all Lilly insulins, including for Humalog® (insulin lispro), will be used by helpline operators to find answers that best fit the personal circumstances of patients....
Jun 29, 2018 06:45 am ET
Lilly Announces Initiation of the Observational Survey of the Epidemiology, Treatment and Care of Migraine (OVERCOME) to Advance Understanding of Burden, Impact and Epidemiology of Migraine
INDIANAPOLIS, June 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today initiation of the ObserVational Survey of the Epidemiology, tReatment and Care Of MigrainE (OVERCOME) study, which aims to be the largest study of its kind in the field of migraine, engaging 40,000 people with migraine throughout the U.S. during the next two years. The objectives of the study are to further understand the burden of migraine and the stigma experienced by people living with migraine, identify barriers to the use of preventive and acute treatments for migraine and to assess how the int...
Jun 28, 2018 04:30 pm ET
Lilly Confirms Date and Conference Call for Second-Quarter 2018 Financial Results Announcement
INDIANAPOLIS, June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the second quarter of 2018 on Tuesday, July 24, 2018. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance....
Jun 28, 2018 06:45 am ET
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz® (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
INDIANAPOLIS, June 28, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz® (ixekizumab) met the primary and major secondary endpoints in COAST-W, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). This is the first AS study focusing on a difficult-to-treat population of patients who had an inadequate response to one or two tumor necrosis factor (TNF) inhibitors (90 percent of enrolled patients) or intolerance to a TNF inhibitor (10 percent)....
Jun 27, 2018 04:32 pm ET
AHS 2018: Lilly's Emgality™ (galcanezumab-gnlm) Significantly Reduced Monthly Migraine Headache Days in Patients with Migraine Who Previously Failed BOTOX®* (onabotulinumtoxinA)
INDIANAPOLIS, June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today results from a post-hoc analysis which demonstrated efficacy of Emgality™  (galcanezumab-gnlm) in patients with episodic and chronic migraine who had previously failed preventive treatment with BOTOX®* (onabotulinumtoxinA). Detailed results from a post-hoc analysis of three Phase 3 studies (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented as a late-breaking presentation on Saturday, June 30 at the American Headache Society (AHS) annual meeting in San Francisco....
Jun 27, 2018 04:27 pm ET
AHS 2018: Lilly Highlights Positive Phase 3 Results from the Largest Controlled Preventive Trial in Episodic Cluster Headache
INDIANAPOLIS, June 27, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today full results from a positive Phase 3 study of patients with episodic cluster headache treated with Emgality™ (galcanezumab-gnlm). Detailed primary and secondary results will be presented Saturday, June 30 as a late-breaking presentation at the American Headache Society (AHS) annual meeting in San Francisco....
Jun 25, 2018 08:00 am ET
Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced that both randomized controlled trials in the EASE Phase III program, investigating the use of empagliflozin in combination with insulin therapy in adults with type 1 diabetes, met their primary endpoint. The primary efficacy endpoint, defined in both trials as placebo-corrected change from baseline in A1C after 26 weeks of treatment, was met for all investigated doses of empagliflozin (2.5, 10 and 25 mg)....
Jun 25, 2018 08:00 am ET
First-ever Study of Lilly's Humulin® R U-500 Administered in an Insulin Pump Shows Improved A1C in People with Type 2 Diabetes
INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Eli Lilly and Company's (NYSE: LLY) Humulin® R U-500 administered via an investigational insulin pump (Omnipod® U-500™ Insulin Management System)  provided greater A1C reduction with less daily insulin needed compared to multiple daily injections (MDI) in adults with type 2 diabetes on high dose insulin (201-600 units/day).1 Data from this phase 3 study will be presented for the first time today in an oral session at the American Diabetes Association (ADA) 78th Scientific Sessions® in Orlando. Humulin R U-500 is Lilly's highly concentrated insulin ...
Jun 25, 2018 06:45 am ET
Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache
INDIANAPOLIS, June 25, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today it will present Phase 3 data for galcanezumab and lasmiditan, two investigational, non-opioid treatments for migraine and cluster headache, at the American Headache Society (AHS) annual meeting taking place June 28-July 1 in San Francisco. ...
Jun 24, 2018 09:00 am ET
Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW
INDIANAPOLIS, June 24, 2018 /PRNewswire/ -- People with type 2 diabetes new to treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist (RA) had better blood sugar control, were more likely to adhere to treatment and stayed on treatment longer with once-weekly Trulicity® (dulaglutide) compared to once-daily liraglutide and once-weekly exenatide QW according to real-world data.1,2 These data are being presented at the American Diabetes Association's (ADA) 78th Scientific Sessions® in Orlando. Trulicity is Eli Lilly and Company's (NYSE: LLY) once-weekly, injectable GLP-1 RA approved t...
Jun 23, 2018 10:00 am ET
Jardiance® reduced risk of kidney disease progression in adults with type 2 diabetes and established cardiovascular (CV) disease independent of control of conventional CV risk factors
RIDGEFIELD, Conn. and INDIANAPOLIS, June 23, 2018 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced findings from two new analyses of the landmark EMPA-REG OUTCOME® trial, presented at the 78th American Diabetes Association (ADA) Scientific Sessions®. Results include a post-hoc analysis demonstrating consistent effects for Jardiance® versus placebo on renal outcomes in patients with established cardiovascular (CV) disease and type 2 diabetes, irrespective of control of certain CV risk factors....